| Development and trends of biosurfactant analysis and purification using rhamnolipids as an example M Heyd, A Kohnert, TH Tan, M Nusser, F Kirschhöfer, G Brenner-Weiss, ... Analytical and bioanalytical chemistry 391, 1579-1590, 2008 | 259 | 2008 |
| Micropilot: automation of fluorescence microscopy–based imaging for systems biology C Conrad, A Wünsche, TH Tan, J Bulkescher, F Sieckmann, F Verissimo, ... Nature methods 8 (3), 246-249, 2011 | 162 | 2011 |
| Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis KE Steele, TH Tan, R Korn, K Dacosta, C Brown, M Kuziora, ... Journal for immunotherapy of cancer 6, 1-14, 2018 | 108 | 2018 |
| Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy S Althammer, TH Tan, A Spitzmüller, L Rognoni, T Wiestler, T Herz, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 104 | 2019 |
| Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial T Cascone, G Kar, JD Spicer, R García-Campelo, W Weder, DB Daniel, ... Cancer discovery 13 (11), 2394-2411, 2023 | 52 | 2023 |
| Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells MA Silva, N Triltsch, S Leis, I Kanchev, TH Tan, B Van Peel, ... The Journal of Pathology: Clinical Research 6 (2), 124-137, 2020 | 19 | 2020 |
| 929MO Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small cell lung cancer (NSCLC … J Spicer, T Cascone, G Kar, Y Zheng, J Blando, TH Tan, M Cheng, ... Annals of Oncology 33, S971, 2022 | 9 | 2022 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016 S Althammer, K Steele, M Rebelatto, TH Tan, T Wiestler, G Schmidt, ... Journal for ImmunoTherapy of Cancer 4, 223-242, 2016 | 9 | 2016 |
| Combinatorial CD8+ and PD-L1+ cell densities correlate with response and improved survival in non-small cell lung cancer (NSCLC) patients treated with durvalumab S Althammer, K Steele, M Rebelatto, TH Tan, T Wiestler, G Schmidt, ... J Immunother Cancer 4 (suppl 2), 91, 2016 | 4 | 2016 |
| Quantitative continuous scoring of PD-L1 for superior patient selection for anti-PD-L1 treatment of locally advanced or unresectable NSCLC JM Lesniak, I Bisha, S Christ, L Meinecke, T Padel, LS Monasor, ... Cancer Research 84 (6_Supplement), 7617-7617, 2024 | 1 | 2024 |
| Quantitative assessment of IHC using computational pathology allows superior patient selection for biomarker-informed patients H Sade, A Kapil, P Wortmann, A Spitzmueller, N Triltsch, L Meinecke, ... Cancer Research 82 (12_Supplement), 468-468, 2022 | 1 | 2022 |
| Insights into the tumour immune microenvironment using tissue phenomics to drive cancer immunotherapy M Groher, J Zimmermann, H Musa, A Ackermann, M Surace, ... Annals of Oncology 30, v505, 2019 | 1 | 2019 |
| The prognostic and predictive roles of a CD8/PD-L1 signature in cancer S Althammer, K Steele, M Widmaier, C Brown, TH Tan, L Rognoni, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 5, 2017 | 1 | 2017 |
| 1173P Combining mass spectrometry with quantitative continuous scoring to unlock the full quantitative potential of immunohistochemistry A Hidalgo-Sastre, J Zaucha, N Damond, TH Tan, A Meier, M Schick, ... Annals of Oncology 35, S762-S763, 2024 | | 2024 |
| Multiplex immunofluorescence profiling of the tumor microenvironment and CD73: Activity of neoadjuvant oleclumab in patients with non-small-cell lung cancer in NeoCOAST I Bisha, TH Tan, M Weitkunat, A Andoni, I Dino, P Martin, M Saraiya, ... Cancer Research 84 (6_Supplement), 2023-2023, 2024 | | 2024 |
| Development and implementation of image analysis-based Quantitative Continuous Score (QCS) for B7-H4 IHC to understand AZD8205 pharmacodynamics P Wortmann, TH Tan, S Haneder, AE Storti, A Kapil, J Chesebrough, ... Cancer Research 82 (12_Supplement), 452-452, 2022 | | 2022 |
| P1. 09-16 Tumor Proliferation Is Associated with the Tumor Immunological Status: A Study on NSCLC Using Multiplex Immunofluorescence A Spitzmüller, TH Tan, M Surace, L Rognoni, D Chain, V Pawar, ... Journal of Thoracic Oncology 14 (10), S502, 2019 | | 2019 |
| Dissemination score of CD8+ TILs by automated image analysis is a potential marker of immune activity in human cancers S Bentink, A Spitzmueller, TH Tan, H Sade, S Wu, BW Higgs, KE Steele Cancer Research 79 (13_Supplement), 2795-2795, 2019 | | 2019 |
| Abstract A069: Combination of immune status and tumor microvascularization provides strong prognostic markers for prostate cancer recurrence prediction N Harder, M Athelogou, H Hessel, A Buchner, C Stief, T Kirchner, ... Cancer Research 78 (16_Supplement), A069-A069, 2018 | | 2018 |
| Combination of immune status and tumor microvascularization provides strong prognostic markers for prostate cancer recurrence prediction. N Harder, M Athelogou, H Hessel, A Buchner, C Stief, T Kirchner, ... CANCER RESEARCH 78 (16), 62-62, 2018 | | 2018 |
